Hypertension, Vol 2, 169-176, Copyright © 1980 by American Heart Association
S Sen, RC Tarazi and FM Bumpus
The potent converting enzyme inhibitor (CEI) SQ14,225, which is known to
prevent the formation of angiotensin II (AII) has been used to evaluate the
role of AII in the development and reversal of cardiac hypertrophy. The
present study describes the effect of CEI on blood pressure (BP) and
myocardial hypertrophy (prevention and reversal) in the spontaneously
hypertensive rat (SHR). A group of 3-week- and 8-week- old male SHR was
treated with CEI (30 mg/kg in drinking water) for 6 weeks. An additional
group of SHR was also treated with a combination of CEI and a diuretic
(hydrochlorothiazide, 500 mg/liter). Heart weight, BP, deoxyribonucleic
acid (DNA), ribonucleic acid (RNA), hydroxyproline, myocardial
catecholamines, and plasma renin activity (PRA) were determined. In the
prevention study, we found a significant reduction in the ratio of heart
weight to body weight along with the prevention of hypertension (200 vs 145
mm Hg, p less than 0.001). Similar reductions in BP and heart weights were
obtained with the reversal group. A better BP control was noted in the CEI
and hydrochlorothiazide group. The reduction of heart weight was associated
with a reduction in RNA and hydroxyproline content. In all groups, we found
a significant increase in PRA (p less than 0.001) and a slight increase in
tissue catecholamine concentration. No change in kidney weight was found in
any group. Data clearly showed that oral administration of CEI prevented
and reversed cardiac hypertrophy in SHR. Reversal was associated with a
decrease in myocardial collagen content. These data indicate that
prevention of AII formation in combination with BP control can prevent and
reverse cardiac hypertrophy in SHR. Of course, whether or not CEI acts only
through the renin angiotension system is still speculative.
ARTICLES
Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats
This article has been cited by other articles:
 |
|
 |
|
  K. Nagata, F. Somura, K. Obata, M. Odashima, H. Izawa, S. Ichihara, T. Nagasaka, M. Iwase, Y. Yamada, N. Nakashima, et al. AT1 Receptor Blockade Reduces Cardiac Calcineurin Activity in Hypertensive Rats Hypertension, August 1, 2002; 40(2): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G Brilla Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs Cardiovasc Res, May 1, 2000; 46(2): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Magga, O. Vuolteenaho, M. Marttila, and H. Ruskoaho Endothelin-1 Is Involved in Stretch-Induced Early Activation of B-Type Natriuretic Peptide Gene Expression in Atrial but Not in Ventricular Myocytes : Acute Effects of Mixed ETA/ETB and AT1 Receptor Antagonists In Vivo and In Vitro Circulation, November 4, 1997; 96(9): 3053 - 3062. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Sil, D. Mukherjee, and S. Sen Quantification of Myotrophin From Spontaneously Hypertensive and Normal Rat Hearts Circ. Res., June 1, 1995; 76(6): 1020 - 1027. [Abstract] [Full Text]
|
|
|
|
|
|
T. Kohya, H. Yokoshiki, N. Tohse, M. Kanno, H. Nakaya, H. Saito, and A. Kitabatake Regression of Left Ventricular Hypertrophy Prevents Ischemia-Induced Lethal Arrhythmias : Beneficial Effect of Angiotensin II Blockade Circ. Res., May 1, 1995; 76(5): 892 - 899. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. M. Cummings, P. Amadio Jr, L. Nelson, and J. M. Fitzgerald The Role of Calcium Channel Blockers in the Treatment of Essential Hypertension Arch Intern Med, February 1, 1991; 151(2): 250 - 259. [Abstract] [PDF]
|
|
|
|
|
|
R. N. Re Cellular Biology of the Renin-Angiotensin Systems Arch Intern Med, October 1, 1984; 144(10): 2037 - 2041. [Abstract] [PDF]
|
|